Human Mixtard Suspension for Injection 40IU/ml is a premixed insulin formulation containing 70% Insulin Isophane (NPH insulin) and 30% soluble Human Insulin, designed for the management of diabetes mellitus requiring insulin therapy. This suspension provides both intermediate-acting and short-acting insulin components, enabling effective glycemic control by addressing both basal and prandial insulin requirements. Insulin Isophane acts to maintain basal insulin levels over an extended period, while the soluble Human Insulin component facilitates rapid onset of action to manage postprandial glucose excursions. Human Mixtard is indicated for patients with type 1 diabetes mellitus and for those with type 2 diabetes mellitus when diet, exercise, and oral hypoglycemic agents alone do not provide adequate glycemic control. The suspension should be administered subcutaneously, with dosage individualized based on patient response, blood glucose monitoring, and lifestyle factors. Proper resuspension of the suspension prior to injection is essential to ensure uniform insulin concentration. As with all insulin preparations, monitoring for hypoglycemia is critical, particularly during initiation or dose adjustments. This product should be stored under recommended conditions to maintain potency and efficacy. Human Mixtard Suspension offers a convenient and effective insulin therapy option for comprehensive diabetes management.